Fast-fashion giant Shein is facing significant hurdles in its pursuit of a Hong Kong stock exchange listing, with profitability concerns casting a long shadow over its ambitions. The company, which built its
A Texas appeals court has reversed a trial court’s ruling against two will contestants who alleged that a page in their father’s will had been forged or altered. The case, Estate of
More
Matthew Cali has filed claims against Troutman Pepper Locke, alleging the firm moved the goalposts on his path to partnership following a serious cardiac episode. Cali says he survived a devastating heart
More
The US stock market is displaying a rare technical pattern that has not been observed since the year 2000, raising fresh concerns among market watchers. The year 2000 comparison carries significant weight,
More
A significant share price decline of 58.9% has raised serious questions about one FTSE 100 company’s ability to retain its place in the index. Companies in the FTSE 100 are ranked by
More
Nike’s former global editor-in-chief, Dan Rookwood, argues that brands routinely squander their most valuable asset: time with extraordinary athletic talent. Rookwood spent years interviewing athletes after landing his first role on The
More
Governor Josh Shapiro signed Executive Order 2026-05 on August 18, 2026, titled “Protecting Pennsylvania Consumers from Data Center Impacts,” introducing sweeping new requirements for data centre development across the state. The order
More
Persimmon, one of the UK’s largest housebuilders, has suffered a staggering 58.9% decline in its share price over the past five years. The stock has now been flagged for likely relegation from
More
The US stock market is reportedly flashing a rare technical signal that has only been observed three times across nearly 156 years of recorded financial history. Historians and market analysts who study
More
Britain’s tax authority is preparing to send officials to inspect high-value homes as part of a sweeping reform to the council tax system targeting wealthy properties. HMRC agents will assess architectural styles,
More
Amgen and AstraZeneca’s Tezspire has delivered a significant phase 3 clinical win in eosinophilic esophagitis, intensifying competition with Sanofi and Regeneron’s Dupixent. The companies announced that the phase 3 CROSSING trial hit
More